@Article{Pałgan2018,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="35",
number="5",
year="2018",
title="Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma",
abstract="Asthma is a multiphenotypic disease, and therapeutic management in patients with severe asthma is particularly difficult, with conventional treatment of severe asthma showing poor efficacy. The inclusion of omalizumab as adjunctive therapy improves asthma control. The studies conducted have shown that omalizumab significantly improves FEV1 after 3 and 12 months of treatment.",
author="Pałgan, Krzysztof
and Żbikowska-Götz, Magdalena
and Lis, Kinga
and Chrzaniecka, Elżbieta
and Bartuzi, Zbigniew",
pages="495--497",
doi="10.5114/ada.2018.77241",
url="http://dx.doi.org/10.5114/ada.2018.77241"
}